Brucellosis and sacroiliitis: A common presentation of an uncommon pathogen

Journal of the American Board of Family Medicine

Volumn 21, Issue 2, 2008, Pages 158-161

  Priest, James R ^a   Low, Dennis ^b   Wang, Cliff ^b   Bush, Thomas ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SANTA CLARA VALLEY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXYCYCLINE; GENTAMICIN; IMMUNOGLOBULIN M; RIFAMPICIN;

ADULT; ARTICLE; BACKACHE; BRUCELLA ABORTUS; BRUCELLOSIS; CASE REPORT; CHEESE; COUGHING; EL SALVADOR; FEVER; HUMAN; HUMAN TISSUE; MALE; ORCHITIS; PASTEURIZATION; SACROILIAC JOINT; SACROILIITIS; SERODIAGNOSIS;

ADULT; ANTI-BACTERIAL AGENTS; ARTHRITIS, INFECTIOUS; BRUCELLA ABORTUS; BRUCELLOSIS; CHEESE; DIAGNOSIS, DIFFERENTIAL; DOXYCYCLINE; GENTAMICINS; HUMANS; LOW BACK PAIN; MALE; ORCHITIS; RIFAMPIN; SACROILIAC JOINT;

EID: 41549128911     PISSN: 15572625     EISSN: 15587118     Source Type: Journal    
DOI: 10.3122/jabfm.2008.02.070170     Document Type: Article

References (27)

1. Hing E, Cherry DK, Woodwell DA. National Ambulatory Medical Care Survey: 2004 summary. Adv Data 2006;(374):1-33.
2. Middleton KR, Hing E. National Hospital Ambulatory Medical Care Survey: 2004 outpatient department summary. Adv Data 2006;(373):1-27.
3. Gonzalez-Gay MA, Garcia-Porrua C, Ibanez D, Garcia-Pais MJ. Osteoarticular complications of brucellosis in an Atlantic area of Spain. J Rheumatol 1999;26:141-5.
4. Park MY, Lee CS, Choi YS, Park SJ, Lee JS, Lee HB. A sporadic outbreak of human brucellosis in Korea. J Korean Med Sci 2005;20:941-6.
5. Ashford DA, di Pietra J, Lingappa J, et al. Adverse events in humans associated with accidental exposure to the livestock brucellosis vaccine RB51. Vaccine 2004;22:3435-9.
6. Jimenez de Bagues MP, Dudal S, Dornand J, Gross A. Cellular bioterrorism: how Brucella corrupts macrophage physiology to promote invasion and proliferation. Clin Immunol 2005;114:227-38.
7. Al Sekait M. Seroepidemiological survey of brucellosis antibodies in Saudi Arabia. Ann Saudi Med 1999;19:219-22.
8. Pappas G, Panagopoulou P, Christou L, Akritidis N. Brucella as a biological weapon. Cell Mol Life Sci 2006;63:2229-36.
9. Troy SB, Rickman LS, Davis CE. Brucellosis in San Diego: epidemiology and species-related differences in acute clinical presentations. Medicine (Baltimore) 2005;84:174-87.
10. Cetinkaya Z, Aktepe OC, Ciftci IH, Demirel R. Seroprevalence of human brucellosis in a rural area of Western Anatolia, Turkey. J Health Popul Nutr 2005;23:137-41.
11. Lopez-Merino A, Migranas-Ortiz R, Perez-Miravete A, et al. [Seroepidemiology of brucellosis in Mexico]. Salud Publica Mex 1992;34:230-40.
12. Reid AJ. Brucellosis a persistent occupational hazard in Ireland. Int J Occup Environ Health 2005;11:302-4.
13. Torre I, Ribera G, Pavia M, Angelillo IF. A seroepidemiologic survey on brucellosis antibodies in southern Italy. Infection 1997;25:150-3.
14. McNabb SJ, Jajosky RA, Hall-Baker PA, et al. Summary of notifiable diseases United States, 2005. MMWR Morb Mortal Wkly Rep 2007;54:1-92.
15. Al Dahouk S, Nockler K, Hensel A, et al. Human brucellosis in a nonendemic country: a report from Germany, 2002 and 2003. Eur J Clin Microbiol Infect Dis 2005;24:450-6.
16. Bouza E, Sanchez-Carrillo C, Hernangomez S, Gonzalez MJ. Laboratory-acquired brucellosis: a Spanish national survey. J Hosp Infect 2005;61:80-3.
17. Noviello S, Gallo R, Kelly M, et al. Laboratory-acquired brucellosis. Emerg Infect Dis 2004;10:1848-50.
18. Colmenero JD, Reguera JM, Martos F, et al. Complications associated with Brucella melitensis infection: a study of 530 cases. Medicine (Baltimore) 1996;75:195-211.
19. Dokuzoguz B, Ergonul O, Baykam N, et al. Characteristics of B. melitensis versus B. abortus bacteraemias. J Infect 2005;50:41-5.
20. Pourbagher MA, Pourbagher A, Savas L, et al. Clinical pattern and abdominal sonographic findings in 251 cases of brucellosis in southern Turkey. AJR AJR 2006;187:W191-4.
21. Press J, Peled N, Buskila D, Yagupsky P. Leukocyte count in the synovial fluid of children with cultureproven brucellar arthritis. Clin Rheumatol 2002;21:191-3.
22. Ersoy Y, Sonmez E, Tevfik MR, But AD. Comparison of three different combination therapies in the treatment of human brucellosis. Trop Doct 2005;35:210-2.
23. El Miedany YM, El Gaafary M, Baddour M, Ahmed I. Human brucellosis: do we need to revise our therapeutic policy?. J Rheumatol 2003;30:2666-72.
24. Bayindir Y, Sonmez E, Aladag A, Buyukberber N. Comparison of five antimicrobial regimens for the treatment of brucellar spondylitis: a prospective, randomized study. J Chemother 2003;15:466-71.
25. Solera J, Lozano E, Martinez-Alfaro E, Espinosa A, Castillejos ML, Abad L. Brucellar spondylitis: review of 35 cases and literature survey. Clin Infect Dis 1999;29:1440-9.
26. Solera J, Martinez-Alfaro E, Espinosa A, Castillejos ML, Geijo P, Rodriguez-Zapata M. Multivariate model for predicting relapse in human brucellosis. J Infect 1998;36:85-92.
27. Hasanjani Roushan MR, Mohraz M, Hajiahmadi M, Ramzani A, Valayati AA. Efficacy of gentamicin plus doxycycline versus streptomycin plus doxycycline in the treatment of brucellosis in humans. Clin Infect Dis 2006;42:1075-80.